Chaperon is showing strong performance. The news that it published preclinical results of next-generation cancer immunotherapy technology targeting cancer stem cells in an international professional journal appears to be influencing its stock price. The market for immuno-oncology drugs targeting cancer stem cells is rapidly growing. According to the industry, the related market is expected to reach approximately $2.4 billion this year and $5.7 billion by 2033.
At 10:22 AM on the 17th, Chaperon was trading at 2,065 KRW, up 16.67% from the previous day.
Chaperon, a bio company developing innovative immuno-oncology drugs, announced that it published outstanding preclinical results of next-generation cancer immunotherapy technology targeting cancer stem cells in the international professional journal Biomedicine & Pharmacotherapy (Impact Factor (IF) 7.5). This immuno-oncology technology is being jointly developed by Chaperon and researchers from Seoul National University College of Medicine.
The cancer stem cell-targeting immuno-oncology technology was confirmed to not only activate the proliferation of T cells that kill cancer in mouse tumor models but also increase the production of interferon-gamma, which enhances immune responses. Notably, it inhibited melanoma growth by 91.2% and blocked lung metastasis by 97%, showing excellent results.
The cancer stem cell-targeting antigen announced by Chaperon is expressed in stem cells of various cancers such as colorectal cancer, breast cancer, and lung cancer, and is a protein associated with cancer proliferation and resistance to immunotherapy. The research team believes that removing cancer stem cells through this target antigen can induce sufficient anti-cancer immune responses, enabling effective cancer treatment.
Cancer stem cells suppress anti-cancer immune responses and increase resistance to immuno-oncology drugs. For this reason, efforts to effectively eliminate cancer stem cells to improve the efficacy of immuno-oncology drugs continue, but there are very few commercialized cases.
A Chaperon representative said, “This next-generation cancer immunotherapy technology is significant in that it has evolved immuno-oncology technology by newly discovering a promising target antigen that can efficiently eliminate cancer stem cells,” adding, “We expect it to be an excellent alternative to existing immuno-oncology drugs, which have low clinical remission rates and frequent relapses, through new drug development.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
